Stock AKBA AKEBIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.34 USD +0.75% Intraday chart for Akebia Therapeutics, Inc. -1.47% +8.06%
Apr. 23 Averoa Seeks EU Approval for Chronic Kidney Disease Drug MT
Apr. 16 Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement CI

Evolution of the average Target Price on Akebia Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f307a2ff3e0c4.jJMZRcpCO-EU68ZvRg_jLinVRtZ1okQ2zPAsue_vPl4.ufRzGqlvQqdDmfANBF6LGm6zP6Y0miZihaFKlKuHUB_hyU80gyppmHCh8g~1fbfc3459f126f7bf8ecd52b876041c3

Analyst Recommendations on Akebia Therapeutics, Inc.

HC Wainwright Adjusts Price Target on Akebia Therapeutics to $5 From $3.75, Maintains Buy Rating MT
HC Wainwright Upgrades Akebia Therapeutics to Buy From Neutral MT
Piper Sandler Upgrades Akebia Therapeutics to Overweight From Neutral, Adjusts Price Target to $4 From $2 MT
HC Wainwright Adjusts Price Target on Akebia Therapeutics to $2 From $1.25, Maintains Neutral Rating MT
HC Wainwright Trims Akebia Therapeutics' Price Target to $1.25 From $2, Neutral Rating Kept MT
BTIG Downgrades Akebia Therapeutics to Neutral From Buy MT
HC Wainwright Downgrades Akebia Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $10 MT
Needham Downgrades Akebia Therapeutics to Hold From Buy MT
Mizuho Securities Downgrades Akebia Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $6 MT
Piper Sandler Downgrades Akebia Therapeutics to Neutral From Overweight, Adjusts Price Target to $2 From $8 MT
HC Wainwright Adjusts Akebia Therapeutics' Price Target to $10 From $6, Keeps Buy Rating MT
AKEBIA THERAPEUTICS : Cantor Fitzgerald Initiates Coverage on Akebia Therapeutics With Overweight Rating, $8 Price Target MT
AKEBIA THERAPEUTICS : HC Wainwright & Co. Adjusts Price Target on Akebia Therapeutics to $6 From $9, Maintains Buy Rating MT
AKEBIA THERAPEUTICS : JPMorgan Downgrades Akebia Therapeutics to Underweight From Neutral MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.33 USD
Average target price
5 USD
Spread / Average Target
+275.94%
High Price Target
6 USD
Spread / Highest target
+351.13%
Low Price Target
4 USD
Spread / Lowest Target
+200.75%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Akebia Therapeutics, Inc.

HC Wainwright
Piper Sandler
Mizuho Securities
Needham & Co.
BTIG
Cantor Fitzgerald
J.P. Morgan Chase

Ratings for Akebia Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AKBA Stock
  4. Consensus Akebia Therapeutics, Inc.